Literature DB >> 9824017

Dyspnea in obese healthy men.

H Sahebjami1.   

Abstract

STUDY
OBJECTIVES: To determine whether obese, apparently healthy individuals experience dyspnea at rest and, if so, whether their pulmonary function test (PFT) profile and maximal respiratory pressures are different from obese, healthy subjects without dyspnea.
DESIGN: Prospective, open.
SETTING: Pulmonary function test laboratory, Veterans Administration Medical Center. PATIENTS: Twenty-three obese male subjects (each with a body mass index [BMI] of > 28 kg/m2) with an FEV1 level and an FEV1/FVC ratio > or = 80% of predicted and no coexisting conditions. Fifteen complained of dyspnea, where eight denied having it, at rest. MEASUREMENTS AND
RESULTS: Standard PFT parameters and maximum static inspiratory (P(Imax)) and expiratory (P(Emax)) mouth pressures were determined. Subjects with dyspnea had similar age and height but larger body weight (113.9+/-5.0 vs 97.4+/-2.6 kg, p = 0.03) and BMI (37.4+/-1.6 vs 31.8+/-0.7 kg/m2, p = 0.02) than subjects without dyspnea, and a greater number of them were current or previous smokers. Forced expiratory flow at 75% vital capacity (54.9+/-6 vs 75.5+/-7% predicted, p = 0.05), maximum voluntary ventilation (MVV; 90.2+/-3.8 vs 107.8+/-9.3% predicted, p = 0.05), and P(Emax) (77+/-2 vs 97.8% predicted, p = 0.007) were significantly reduced in the group of subjects with dyspnea. Large airway function (FVC, FEV1, and FEV1/FVC ratio), lung volumes, and gas exchange parameters were similar between the two groups.
CONCLUSIONS: Some obese, but otherwise healthy, individuals experience dyspnea at rest. Reduced P(Emax) and MVV combined with greater body mass and peripheral airway disease are most likely responsible for the sensation of dyspnea in these individuals.

Entities:  

Mesh:

Year:  1998        PMID: 9824017     DOI: 10.1378/chest.114.5.1373

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  Obesity, respiratory function and breathlessness.

Authors:  G J Gibson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  Oxygen cost of breathing and breathlessness during exercise in nonobese women and men.

Authors:  Santiago Lorenzo; Tony G Babb
Journal:  Med Sci Sports Exerc       Date:  2012-06       Impact factor: 5.411

Review 3.  Altered respiratory physiology in obesity.

Authors:  Krishnan Parameswaran; David C Todd; Mark Soth
Journal:  Can Respir J       Date:  2006 May-Jun       Impact factor: 2.409

4.  Maximal expiratory pressure in residential and non-residential school children.

Authors:  Dipayan Choudhuri; Manjunath Aithal; Vasant A Kulkarni
Journal:  Indian J Pediatr       Date:  2002-03       Impact factor: 1.967

Review 5.  Obesity as a Conditioning Factor for High-Altitude Diseases.

Authors:  Rocío San Martin; Julio Brito; Patricia Siques; Fabiola León-Velarde
Journal:  Obes Facts       Date:  2017-08-16       Impact factor: 3.942

Review 6.  Ozone Exposure, Cardiopulmonary Health, and Obesity: A Substantive Review.

Authors:  Patricia D Koman; Peter Mancuso
Journal:  Chem Res Toxicol       Date:  2017-06-15       Impact factor: 3.739

7.  Peak expiratory flow as a predictor of subsequent disability and death in community-living older persons.

Authors:  Carlos A Vaz Fragoso; Evelyne A Gahbauer; Peter H Van Ness; John Concato; Thomas M Gill
Journal:  J Am Geriatr Soc       Date:  2008-04-18       Impact factor: 5.562

Review 8.  Environmental perturbations: Obesity.

Authors:  Stephanie A Shore
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

9.  Dyspnea on exertion in obese men.

Authors:  Vipa Bernhardt; Helen E Wood; Raksa B Moran; Tony G Babb
Journal:  Respir Physiol Neurobiol       Date:  2012-10-17       Impact factor: 1.931

10.  Multidimensional aspects of dyspnea in obese patients referred for cardiopulmonary exercise testing.

Authors:  Bryce N Balmain; Kyle Weinstein; Vipa Bernhardt; Rubria Marines-Price; Andrew R Tomlinson; Tony G Babb
Journal:  Respir Physiol Neurobiol       Date:  2019-12-30       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.